The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Move comes amid rising regulatory pressures
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
By cutting pain crises & boosting haemoglobin
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Subscribe To Our Newsletter & Stay Updated
